User menu

AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies

Bibliographic reference Van Den Neste, Eric ; Van den Berghe, Georges ; Bontemps, Françoise. AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies. In: Expert Opinion on Investigational Drugs : authoritative analysis of R&D trends, Vol. 19, no. 4, p. 571-578 (2010)
Permanent URL
  1. Gruber H. E., Hoffer M. E., McAllister D. R., Laikind P. K., Lane T. A., Schmid-Schoenbein G. W., Engler R. L., Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury, 10.1161/01.cir.80.5.1400
  2. Vincent M. F., Marangos P. J., Gruber H. E., van den Berghe G., Inhibition by AICA Riboside of Gluconeogenesis in Isolated Rat Hepatocytes, 10.2337/diab.40.10.1259
  3. Hardie D. Grahame, Hawley Simon A., Scott John W., AMP-activated protein kinase - development of the energy sensor concept : AMPK - development of the energy sensor concept, 10.1113/jphysiol.2006.108944
  4. Sullivan Jane E., Brocklehurst Katy J., Marley Anna E., Carey Frank, Carling David, Beri Raj K., Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase, 10.1016/0014-5793(94)01006-4
  5. Bochner Barry R., Ames Bruce N., ZTP (5-amino 4-imidazole carboxamide riboside 5′-triphosphate): A proposed alarmone for 10-formyl-tetrahydrofolate deficiency, 10.1016/0092-8674(82)90455-x
  6. Henin N, FASEB J, 9, 541 (1995)
  7. Corton Julia M., Gillespie John G., Hawley Simon A., Hardie D. Grahame, 5-Aminoimidazole-4-Carboxamide Ribonucleoside. A Specific Method for Activating AMP-Activated Protein Kinase in Intact Cells?, 10.1111/j.1432-1033.1995.tb20498.x
  8. Hardie D. Grahame, AMP-activated protein kinase: the guardian of cardiac energy status, 10.1172/jci200422683
  9. Dixon Ross, Gourzis James, McDermott Daniel, Fujitaki James, Dewland Peter, Gruber Harry, AICA-Riboside: Safety, Tolerance, and Pharmacokinetics of a Novel Adenosine-Regulating Agent, 10.1002/j.1552-4604.1991.tb03715.x
  10. Drew Brian G, Kingwell Bronwyn A, Acadesine, an adenosine-regulating agent with the potential for widespread indications, 10.1517/14656566.9.12.2137
  11. Winder WW, Am J Physiol, 277, E1 (1999)
  12. Vincent M. F., Erion M. D., Gruber H. E., Van den Berghe G., Hypoglycaemic effect of AICAriboside in mice, 10.1007/bf02658500
  13. Bergeron R., Previs S. F., Cline G. W., Perret P., Russell III R. R., Young L. H., Shulman G. I., Effect of 5-Aminoimidazole-4-Carboxamide-1- -D-Ribofuranoside Infusion on In Vivo Glucose and Lipid Metabolism in Lean and Obese Zucker Rats, 10.2337/diabetes.50.5.1076
  14. Schimmack Greg, DeFronzo Ralph A., Musi Nicolas, AMP-activated protein kinase: role in metabolism and therapeutic implications, 10.1111/j.1463-1326.2005.00561.x
  15. Consoli A., Nurjhan N., Capani F., Gerich J., Predominant Role of Gluconeogenesis in Increased Hepatic Glucose Production in NIDDM, 10.2337/diab.38.5.550
  16. Erion M. D., van Poelje P. D., Dang Q., Kasibhatla S. R., Potter S. C., Reddy M. R., Reddy K. R., Jiang T., Lipscomb W. N., MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes, 10.1073/pnas.0502983102
  17. van Poelje P. D., Potter S. C., Chandramouli V. C., Landau B. R., Dang Q., Erion M. D., Inhibition of Fructose 1,6-Bisphosphatase Reduces Excessive Endogenous Glucose Production and Attenuates Hyperglycemia in Zucker Diabetic Fatty Rats, 10.2337/db05-1443
  18. Merrill GF, Am J Physiol, 273, E1107 (1997)
  19. Kurth-Kraczek E. J., Hirshman M. F., Goodyear L. J., Winder W. W., 5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle, 10.2337/diabetes.48.8.1667
  20. Narkar Vihang A., Downes Michael, Yu Ruth T., Embler Emi, Wang Yong-Xu, Banayo Ester, Mihaylova Maria M., Nelson Michael C., Zou Yuhua, Juguilon Henry, Kang Heonjoong, Shaw Reuben J., Evans Ronald M., AMPK and PPARδ Agonists Are Exercise Mimetics, 10.1016/j.cell.2008.06.051
  21. Göransson Olga, McBride Andrew, Hawley Simon A., Ross Fiona A., Shpiro Natalia, Foretz Marc, Viollet Benoit, Hardie D. Grahame, Sakamoto Kei, Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein Kinase, 10.1074/jbc.m706536200
  22. Richter Erik A., Kiens Bente, Wojtaszewski Jørgen F.P., Can Exercise Mimetics Substitute for Exercise?, 10.1016/j.cmet.2008.07.004
  23. DeBerardinis Ralph J., Lum Julian J., Hatzivassiliou Georgia, Thompson Craig B., The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation, 10.1016/j.cmet.2007.10.002
  24. Weinberg Frank, Chandel Navdeep S., Mitochondrial Metabolism and Cancer, 10.1111/j.1749-6632.2009.05039.x
  25. Xiang Xiaoqin, Saha Asish K., Wen Rong, Ruderman Neil B., Luo Zhijun, AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms, 10.1016/j.bbrc.2004.06.133
  26. Swinnen Johannes V., Beckers Annelies, Brusselmans Koen, Organe Sophie, Segers Joanna, Timmermans Leen, Vanderhoydonc Frank, Deboel Ludo, Derua Rita, Waelkens Etienne, De Schrijver Ellen, Van de Sande Tine, Noël Agnès, Foufelle Fabienne, Verhoeven Guido, Mimicry of a Cellular Low Energy Status Blocks Tumor Cell Anabolism and Suppresses the Malignant Phenotype, 10.1158/0008-5472.can-04-3025
  27. Rattan Ramandeep, Giri Shailendra, Singh Avtar K., Singh Inderjit, 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside Inhibits Cancer Cell Proliferationin Vitroandin Vivovia AMP-activated Protein Kinase, 10.1074/jbc.m507443200
  28. Baumann Philipp, Mandl-Weber Sonja, Emmerich Bertold, Straka Christian, Schmidmaier Ralf, Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells, 10.1016/j.yexcr.2007.06.020
  29. Beckers A., Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside, 10.1158/1535-7163.mct-06-0001
  30. Garcia-Gil M, Pesi R, Perna S, Allegrini S, Giannecchini M, Camici M, Tozzi M.G, 5′-aminoimidazole-4-carboxamide riboside induces apoptosis in human neuroblastoma cells, 10.1016/s0306-4522(02)00836-9
  31. Pesi Rossana, Micheli Vanna, Jacomelli Gabriella, Peruzzi Luana, Camici Marcella, Garcia-Gil Mercedes, Allegrini Simone, Tozzi Maria Grazia, Cytosolic 5′-nucleotidase hyperactivity in erythrocytes of Lesch–Nyhan syndrome patients : , 10.1097/00001756-200006260-00006
  32. Kefas BA, Diabetologia, 46, 250 (2003)
  33. Meisse Delphine, Van de Casteele Mark, Beauloye Christophe, Hainault Isabelle, Kefas Benjamin A, Rider Mark H, Foufelle Fabienne, Hue Louis, Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells, 10.1016/s0014-5793(02)03110-1
  34. Campas C., Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes, 10.1182/blood-2002-07-2339
  35. Campàs C, Santidrián A F, Domingo A, Gil J, Acadesine induces apoptosis in B cells from mantle cell lymphoma and splenic marginal zone lymphoma, 10.1038/sj.leu.2403593
  36. LÓPEZ José M., SANTIDRIÁN Antonio F., CAMPÀS Clara, GIL Joan, 5-Aminoimidazole-4-carboxamide riboside induces apoptosis in Jurkat cells, but the AMP-activated protein kinase is not involved, 10.1042/bj20021053
  37. Stefanelli Claudio, Stanic’ Ivana, Bonavita Francesca, Flamigni Flavio, Pignatti Carla, Guarnieri Carlo, Caldarera Claudio M., Inhibition of Glucocorticoid-Induced Apoptosis with 5-Aminoimidazole-4-carboxamide Ribonucleoside, a Cell-Permeable Activator of AMP-Activated Protein Kinase, 10.1006/bbrc.1998.8154
  38. Culmsee Carsten, monnig Jennifer, Kemp Bruce E., Mattson Mark P., AMP-Activated Protein Kinase is Highly Expressed in Neurons in the Developing Rat Brain and Promotes Neuronal Survival Following Glucose Deprivation, 10.1385/jmn:17:1:45
  39. Ido Y., Carling D., Ruderman N., Hyperglycemia-Induced Apoptosis in Human Umbilical Vein Endothelial Cells: Inhibition by the AMP-Activated Protein Kinase Activation, 10.2337/diabetes.51.1.159
  40. Blázquez Cristina, Geelen Math J.H, Velasco Guillermo, Guzmán Manuel, The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes, 10.1016/s0014-5793(01)02089-0
  41. Nishino Y, Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection, 10.1016/j.cardiores.2003.10.022
  42. Russell Raymond R., Li Ji, Coven David L., Pypaert Marc, Zechner Christoph, Palmeri Monica, Giordano Frank J., Mu James, Birnbaum Morris J., Young Lawrence H., AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury, 10.1172/jci19297
  43. Jacobs René L., Lingrell Susanne, Dyck Jason R. B., Vance Dennis E., Inhibition of Hepatic Phosphatidylcholine Synthesis by 5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside Is Independent of AMP-activated Protein Kinase Activation, 10.1074/jbc.m605702200
  44. Meley Daniel, Bauvy Chantal, Houben-Weerts Judith H. P. M., Dubbelhuis Peter F., Helmond Mariette T. J., Codogno Patrice, Meijer Alfred J., AMP-activated Protein Kinase and the Regulation of Autophagic Proteolysis, 10.1074/jbc.m605488200
  45. Guigas Bruno, Taleux Nellie, Foretz Marc, Detaille Dominique, Andreelli Fabrizio, Viollet Benoit, Hue Louis, AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside, 10.1042/bj20070105
  46. Imamura Kazuhiro, Ogura Tsutomu, Kishimoto Atsuhiro, Kaminishi Michio, Esumi Hiroyasu, Cell Cycle Regulation via p53 Phosphorylation by a 5′-AMP Activated Protein Kinase Activator, 5-Aminoimidazole- 4-Carboxamide-1-β--Ribofuranoside, in a Human Hepatocellular Carcinoma Cell Line, 10.1006/bbrc.2001.5627
  47. Sengupta Tapas K, Leclerc Gilles M, Hsieh-Kinser Ting, Leclerc Guy J, Singh Inderjit, Barredo Julio C, Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy, 10.1186/1476-4598-6-46
  48. Coll-Mulet L., MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells, 10.1182/blood-2005-08-3273
  49. Keating Michael J., O’Brien Susan, Albitar Maher, Lerner Susan, Plunkett William, Giles Francis, Andreeff Michael, Cortes Jorge, Faderl Stefan, Thomas Deborah, Koller Charles, Wierda William, Detry Michelle A., Lynn Alice, Kantarjian Hagop, Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia, 10.1200/jco.2005.12.051
  50. Wierda William, O’Brien Susan, Wen Sijin, Faderl Stefan, Garcia-Manero Guillermo, Thomas Deborah, Do Kim-Anh, Cortes Jorge, Koller Charles, Beran Miloslav, Ferrajoli Alessandra, Giles Francis, Lerner Susan, Albitar Maher, Kantarjian Hagop, Keating Michael, Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia, 10.1200/jco.2005.12.516
  51. Bosch Francesc, Abrisqueta Pau, Villamor Neus, Terol María José, González-Barca Eva, Ferra Christelle, González Diaz Marcos, Abella Eugenia, Delgado Julio, Carbonell Félix, García Marco José Antonio, Escoda Lourdes, Ferrer Secundino, Monzó Encarnación, González Yolanda, Estany Cristina, Jarque Isidro, Salamero Olga, Muntañola Ana, Montserrat Emili, Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia, 10.1200/jco.2009.22.0442
  52. Shanafelt T. D., Kay N. E., Comprehensive Management of the CLL Patient: A Holistic Approach, 10.1182/asheducation-2007.1.324
  53. Extermann Martine, Hurria Arti, Comprehensive Geriatric Assessment for Older Patients With Cancer, 10.1200/jco.2007.10.6559
  54. Morrison V. A., Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia, 10.1182/asheducation-2007.1.332
  55. Tsimberidou Apostolia-Maria, Keating Michael J., Treatment of fludarabine-refractory chronic lymphocytic leukemia, 10.1002/cncr.24329
  56. O'Brien S., New Agents in the Treatment of CLL, 10.1182/asheducation-2008.1.457
  57. Zenz Thorsten, Benner Axel, Döhner Hartmut, Stilgenbauer Stephan, Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway, 10.4161/cc.7.24.7245
  58. Dearden C., Disease-Specific Complications of Chronic Lymphocytic Leukemia, 10.1182/asheducation-2008.1.450
  59. Maddocks Kami J, Lin Thomas S, Update in the management of chronic lymphocytic leukemia, 10.1186/1756-8722-2-29
  60. Zenz T., Habe S., Denzel T., Mohr J., Winkler D., Buhler A., Sarno A., Groner S., Mertens D., Busch R., Hallek M., Dohner H., Stilgenbauer S., Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial, 10.1182/blood-2009-05-224071
  61. Andersen Niels S., Pedersen Lone B., Laurell Anna, Elonen Erkki, Kolstad Arne, Boesen Anne Marie, Pedersen Lars M., Lauritzsen Grete F., Ekanger Roald, Nilsson-Ehle Herman, Nordström Marie, Fredén Susanne, Jerkeman Mats, Eriksson Mikael, Väärt Jaan, Malmer Beatrice, Geisler Christian H., Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma, 10.1200/jco.2008.21.3116